Asian Pacific association for the study of liver (APASL) guidelines: hepatitis B virus in pregnancy Manoj KumarZaigham AbbasY. H. Zhou Guidelines 03 February 2022 Pages: 211 - 253
Is lean non-alcoholic fatty liver disease a distinct entity? Huapeng LinVincent Wai-Sun Wong Editorial 24 March 2022 Pages: 254 - 256
Management of hepatitis B virus reactivation due to treatment of COVID-19 Terry Cheuk-Fung YipMadeleine GillKen Liu Review Article 02 March 2022 Pages: 257 - 268
Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis Jie Ning YongCheng Han NgNicholas W. S. Chew Review Article 23 March 2022 Pages: 269 - 281
Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study Eiichi OgawaMakoto NakamutaThe Kyushu University Liver Disease Study (KULDS) Group Original Article 25 January 2022 Pages: 282 - 293
Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV–DNA level < 2000 IU/mL Hankil LeeSungin JangBeom Kyung Kim Original Article 24 March 2022 Pages: 294 - 305
CRISPR/Cas13-assisted hepatitis B virus covalently closed circular DNA detection Xiangying ZhangYuan TianFeng Ren Original Article Open access 17 March 2022 Pages: 306 - 315
MRE-based NASH score for diagnosis of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease Young-Sun LeeJi Eun LeeKwan Soo Byun Original Article 07 March 2022 Pages: 316 - 324
Distinctive clinical and genetic features of lean vs overweight fatty liver disease using the UK Biobank Daljeet ChahalDivya SharmaMamatha Bhat Original Article 18 February 2022 Pages: 325 - 336
Gender differences in the association of body composition and biopsy-proved nonalcoholic steatohepatitis Da FangWenjuan TangYan Bi Original Article 24 February 2022 Pages: 337 - 347
Carbohydrate-deficient transferrin is a sensitive marker of alcohol consumption in fatty liver disease Maki MorinagaKazuyoshi KonKenichi Ikejima Original Article 20 January 2022 Pages: 348 - 358
Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice Phillipp HartmannYi DuanBernd Schnabl Original Article Open access 24 January 2022 Pages: 359 - 370
Magnetic resonance elastography and proton density fat fraction predict adverse outcomes in hepatocellular carcinoma Rex Wan-Hin HuiAlbert Chi-Yan ChanWai-Kay Seto Original Article 26 March 2022 Pages: 371 - 380
Image-matching digital macro-slide—a novel pathological examination method for microvascular invasion detection in hepatocellular carcinoma Hong-Ming YuKang WangShu-Qun Cheng Original Article Open access 16 March 2022 Pages: 381 - 395
Abnormal bile acid-microbiota crosstalk promotes the development of hepatocellular carcinoma Rui ShenLixin KeYunpeng Hua Original Article Open access 24 February 2022 Pages: 396 - 411
Serum TERT C228T is an important predictor of non-viral liver cancer with fatty liver disease Norio AkutaYusuke KawamuraHiromitsu Kumada Original Article Open access 20 March 2022 Pages: 412 - 422
A novel machine learning-based radiomic model for diagnosing high bleeding risk esophageal varices in cirrhotic patients Yijie YanYue LiHuiguo Ding Original Article 02 April 2022 Pages: 423 - 432
Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial Anima SharmaAkash RoyRadha K. Dhiman Original Article 28 March 2022 Pages: 433 - 446
Alterations of gut microbiome and metabolite profiles in choledocholithiasis concurrent with cholangitis Zhiyuan HaoKegong TaoYong Lin Original Article 27 July 2021 Pages: 447 - 462
Hepatic tuberculosis masquerading as malignancy Aditya KalePrachi S. PatilSandeep Tandon Original Article 23 October 2021 Pages: 463 - 472
Hepatic tuberculosis: a sheep in wolf’s clothing Suprabhat Giri Letter to the Editor 23 January 2022 Pages: 473 - 474
‘Hepatic tuberculosis: a sheep in wolf’s clothing’. Author response Aditya KalePrachi S. PatilKedar Deodhar Letter to the Editor 10 February 2022 Pages: 475 - 476
Drug-induced liver injury from herbal and dietary supplements: a problem in the East and West alike Emily NashJohn ChetwoodKen Liu Letter to the Editor 23 January 2022 Pages: 477 - 478
Histology activity index: a benchmark for decision making Shaheena ParveenAvinash TiwariAadil Ashraf Letter to the Editor 23 January 2022 Pages: 479 - 479
Immune checkpoint inhibitors in chronic hepatitis B: therapy or high-risk factor for reactivation? Chao CaiHui-Fang ZhangMing-Qin Lu Letter to the Editor 24 March 2022 Pages: 480 - 481
Are immune-checkpoint inhibitors immunosuppressive to hepatitis B virus? George LauMing-Lung YuAlexander Thompson Letter to the Editor 01 March 2022 Pages: 482 - 483
Correction to: Consensus on the secondary prevention of primary liver cancer Yuemin NanXiaoyuan XuChinese Society of Hepatology, Chinese Medical Association Correction Open access 12 January 2022 Pages: 484 - 485
Correction to: APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy George LauMing-Lung YuMasao Omata Correction 25 January 2022 Pages: 486 - 487
Correction to: The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study Yu-Guang ChenChih-Wei YangWu-Chien Chien Correction 16 February 2022 Pages: 488 - 488
